



Eurofins becomes the market leader in non-invasive prenatal testing (NIPT) in Japan with the acquisition of GeneTech Inc.

07 August 2020

Eurofins Scientific (EUFI.PA), the global scientific leader in bioanalytical testing and the European leader in non-invasive prenatal testing (NIPT), announces that it has signed an agreement with Noritsu Koki Co., Ltd. (7744:JP, Tokyo stock exchange) to acquire GeneTech Inc. ("GeneTech"), the pioneer in NIPT and a leading player in genetic analysis in Japan.

GeneTech is the number one player in the NIPT market in Japan and will provide Eurofins access to its equipment and scientific expertise, as well as its clients in Asia which includes renowned specialised medical doctors, major hospitals and clinics. GeneTech operates a laboratory in the Kazusa DNA Research Institute, a public research body founded in 1994 that inaugurated its activity as the world's first institute specialized in DNA-related research. In addition to its NIPT expertise, GeneTech also has testing capabilities in preimplantation genetic testing for aneuploidy (PGT-A) which will expand Eurofins' testing portfolio in Japan.

GeneTech employs over 35 staff and generated revenues over EUR 10m in 2019. As a result of this acquisition, Eurofins will become the leader in the NIPT market in Japan with significant scale advantages over its competitors in the area and will further expand its global service offering in NIPT.

Notes to Editors:

For more information, please visit www.eurofins.com or contact:

Investor Relations
Eurofins Scientific SE
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

About Eurofins – the global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter "Eurofins" or "the Group"), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agrosience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over **48,000 staff** across a network of more than 900 independent companies in over **50 countries** generally specialised by end client markets and operating more than **800 laboratories**, Eurofins offers a portfolio of over **200,000 analytical methods** to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic

testing services. The Group's objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity.